Biogen has upped its presence in gene therapy through a $1bn deal with smaller biotech AGTC. The deal signals the second major biotech deal in a week and gives the smaller Florida-based company a chance to expand its wholly-owned programs.
Biogen announced 02 July that it has agreed to pay $124m upfront and $472.5M in milestones for two ophthalmic disease...







